SIG
ABUS icon

Sargent Investment Group’s Arbutus Biopharma ABUS Stock Holding History

Sargent Investment Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,339
Closed -$37K – 198
2021
Q2 		$37K Buy
+12,339
New +$38.2K 0.01% 203

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sargent Investment Group's ABUS Position: Q3 2021 in Review

Sargent Investment Group sold out of Arbutus Biopharma (ABUS) in Q3 2021, closing a stake of 12,339 shares — an estimated $37K sold.

Sargent Investment Group first reported a position in ABUS in Q2 2021 and held it in 1 quarter. The position peaked at $37K in Q2 2021. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2021.

  • Sargent Investment Group reported no remaining Arbutus Biopharma position as of Q3 2021 after selling out during the quarter.
  • Sargent Investment Group sold 12,339 Arbutus Biopharma shares in Q3 2021, an estimated $37K.
  • Sargent Investment Group first reported a position in Arbutus Biopharma in Q2 2021 and held it in 1 quarter.
  • Sargent Investment Group's Arbutus Biopharma position peaked at $37K in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2021.

Based on Sargent Investment Group's 13F filing for Q3 2021, filed 12 Nov 2021.